Skip to main content
. 2023 Oct 31;16(12):2744–2755. doi: 10.1111/cts.13669

FIGURE 1.

FIGURE 1

Boxplots of acMMAE concentrations by region in patients from the POLARIX PK‐evaluable population receiving polatuzumab vedotin at 1.8 mg/kg as part of the Pola‐R‐CHP regimen, measured at (a) cycle 1 30 min postdose (C max), (b) cycle 4 predose (C trough), and (c) cycle 4 30 min postdose (C max). Box, first and third quartiles; middle bar, median; black circle, observed data points; whiskers, largest observed value within the upper fence (third quartile plus 1.5 × IQR); smallest observed value within the lowest fence (first quartile plus 1.5 × IQR). acMMAE, antibody‐conjugated monomethyl auristatin E; C max, maximum concentration; C trough, last concentration prior to dosing; IQR, interquartile range; min, minutes; MMAE, monomethyl auristatin E; PK, pharmacokinetics; Pola‐R‐CHP, polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin and prednisone.